Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib vs chemotherapy in adjuvant EGFR-mutated NSCLC (ADJUVANT)
NCT01405079Phase 3Unknown
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Sep 2011
- Primary completion
- Mar 2017
- Countries
- 1
01
Overview
A Phase 3 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01405079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01405079.